T-knife is developing Supercharged T cell therapies for patients with solid tumors. T-knife leverages several proprietary technologies to create best-in-class cell therapies, including our MyT humanized mouse platform allowing for efficient discovery of TCRs with high affinity / specificity, and multiple novel armoring technologies designed to improve T cell persistence, fitness, activation, and survival in the TME. T-knife's pipeline includes next-generation TCR-T cell therapy programs targeting PRAME, MAGE-A1, and KRAS. The company's lead program targeting PRAME is in preclinical development. T-knife was founded by leading T-cell and immunology experts using technology developed at the Max Delbruck Center for Molecular Medicine together with Charité – Universitätsmedizin Berlin. The company is based in the US and in Germany and has raised nearly $200M to date from leading life sciences investors, including RA Capital, Versant, EQT, Andera, Casdin, Caas, and others.